...
首页> 外文期刊>Head and neck: Journal for the sciences and specialities of the head and neck >Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland--a review of current recommendations.
【24h】

Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland--a review of current recommendations.

机译:头颈部皮肤鳞状细胞癌转移至腮腺-对当前建议的综述。

获取原文
获取原文并翻译 | 示例
           

摘要

Cutaneous squamous cell carcinoma (SCC) of the head and neck may metastasize in up to 5% of patients, with the parotid lymph nodes the most frequent site for spread. Metastases frequently show delayed presentation after the primary cancer had been treated. The optimum treatment should be surgery followed by adjuvant radiotherapy, with an appropriate parotidectomy, and preservation of the facial nerve if not involved by tumor and treatment to the neck. In a clinically N0 neck, levels I to III should be cleared for facial primaries, levels II to III for anterior scalp and external ear primaries, and levels II to V for posterior scalp primaries. Approximate 5-year disease-specific survival (DSS) after treatment was 70% to 75%. Patients with immunosuppression, in particular transplant recipients, are at high risk of developing aggressive metastatic cutaneous SCC. Modifications of the staging systems have demonstrated the prognostic benefits of accurately staging parotid and/or neck nodal disease.
机译:头颈部皮肤鳞状细胞癌(SCC)可能转移至5%的患者中,腮腺淋巴结是最常扩散的部位。在治疗原发性癌症后,转移瘤经常显示延迟出现。最佳的治疗方法应该是手术,然后进行辅助放疗,并进行适当的腮腺切除术,如果不与肿瘤和颈部治疗无关,则保留面部神经。在临床上为N0颈的面部,应清除I至III级的面部原发,清除II至III级的前头皮和外耳初级,清除II至V级的后部原发。治疗后大约5年疾病特异性存活率(DSS)为70%至75%。具有免疫抑制作用的患者,尤其是移植受者,处于发展侵袭性转移性皮肤SCC的高风险中。分期系统的修改已经证明了准确分期腮腺和/或颈部淋巴结病的预后益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号